|1.||Wang, S: 1 article (04/2015)|
|2.||Zhou, S-N: 1 article (04/2015)|
|3.||Feng, Y-L: 1 article (04/2015)|
|4.||Chen, J: 1 article (04/2015)|
|5.||Zhang, Y-M: 1 article (04/2015)|
|6.||Fei, Yiping: 1 article (11/2014)|
|7.||Zhu, Lei: 1 article (11/2014)|
|8.||Pan, Yujun: 1 article (11/2014)|
|9.||Li, Fangqin: 1 article (11/2014)|
|10.||Zhang, Jiadong: 1 article (11/2014)|
01/01/1987 - "In conclusion, in the present population of patients with mild to moderate degree dementia, 1600 mg/day of oxiracetam was effective in enhancing both attentional activities and other, more complex, neuropsychological functions."
09/01/1992 - "A multicentre, double-blind, between-patient study was carried out to evaluate the efficacy and tolerability of oxiracetam (800 mg tablet), in comparison with placebo, each given twice daily for 12 weeks to patients suffering from primary degenerative, multi-infarct or mixed dementia. "
09/01/1992 - "Oxiracetam in dementia: a double-blind, placebo-controlled study."
01/01/1989 - "The present study, showing positive clinical findings after long-term oxiracetam therapy in controlled conditions, confirms that this drug can be a useful pharmacological treatment for mild to moderate degrees of dementia."
01/01/1987 - "40 out-patients with a mild to moderate degree of dementia (11 less than or equal to MMSE less than 24) participated in a between-subjects (n = 20 + 20) double-blind placebo-controlled randomized trial comparing the effects of oxiracetam 800 mg bid and placebo during 90 days of treatment. "
|2.||Multi-Infarct Dementia (Dementia, Multi Infarct)
01/01/1989 - "Oxiracetam in the treatment of multi-infarct dementia."
01/01/1989 - "2. Because previous studies had not specifically examined the effects of oxiracetam upon dementias of vascular origin, the present study evaluated the therapeutic efficacy and safety of oxiracetam in the treatment of symptoms of multi-infarct dementia (MID) of mild to moderate severity. "
01/01/1992 - "The cognitive and behavioral effects and the safety of oxiracetam therapy during a placebo-controlled trial and the relevant follow-up up to 1 year in patients with senile dementia of Alzheimer type (SDAT) and multi-infarct dementia (MID) of mild to moderate degree were studied. "
01/01/1992 - "Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree."
01/01/1989 - "Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD). "
|3.||Amnesia (Dissociative Amnesia)
08/31/1992 - "In the passive avoidance test the i.c.v. administration of 3.5 micrograms of AP7 caused severe amnesia which was antagonized in a dose-dependent manner by the pretreatment with oxiracetam. "
01/01/1993 - "The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans."
01/01/1993 - "The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. "
12/20/2000 - "Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice."
09/01/1995 - "In conclusion, these data demonstrate that ascorbic acid, alone or in combination with oxiracetam, may prevent experimentally induced amnesia in aged mice."
|4.||Nootropic Agents (Nootropics)
|5.||Acetylcholine (Acetylcholine Chloride)
|7.||Succinic Acid (Succinate)
|8.||Dizocilpine Maleate (Dizocilpine)
|9.||N-Methyl-D-Aspartate Receptors (NMDA Receptors)